Logo

Novartis Reports FDA's Acceptance of BLA for Crizanlizumab (SEG101) to Treat Sickle Cell Disease

Share this

Novartis Reports FDA's Acceptance of BLA for Crizanlizumab (SEG101) to Treat Sickle Cell Disease

Shots:

  • The US FDA has accepted Novartis’ BLA and has granted Priority Review for crizanlizumab to prevent vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD)
  • The FDA submission is based on P-II SUSTAIN study results assessing crizanlizumab (5 mg/kg) vs PBO further resulting in a reduction in VOCs (36% vs 17%)- m-time to first VOC (4.07 vs 1.38 mos.)- 42% reduction in annual rates of hospitalization days
  • Crizanlizumab is a mAb targeting P-selectin mediated multicellular adhesion for the prevention of VOCs in patients with SCD- being evaluated in multiple studies for SCD in different age groups

Click here to read full press release/ article | Ref: Novartis | Image: Novartis


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions